在孕期糖尿病患者中与产后葡萄糖不耐受相关的危险因素:一项元分析研究
Naijun Chen1, Qian Gao1, Tingting Li1
1Endocrinology Department, Affiliated Hospital of Shaoxing University, Shaoxing, Zhejiang, China.
Pakistan journal of pharmaceutical sciences
|June 25, 2025
概括
孕期糖尿病 (GDM) 病史的妇女面临更高的分娩后葡萄糖不耐症的风险. 关键的危险因素包括GDM病史,体重指数升高和怀孕期间使用胰岛素.
科学领域:
- 生殖内分泌学 生殖内分泌学
- 代谢障碍 代谢障碍 代谢障碍
背景情况:
- 孕期糖尿病 (GDM) 病史的妇女在产后患有异常葡萄糖耐受症的风险增加.
- 识别产后葡萄糖不耐受症的危险因素对于预防策略至关重要.
研究的目的:
- 为了确定与孕产后葡萄糖不耐症相关的关键风险因素,在女性有史以来的GDM.
主要方法:
- 进行了一项元分析,审查了8项相关研究.
- 统计分析确定了重要的风险因素及其赔率比率.
主要成果:
- 患有GDM史 (OR=0.877),体重指数 (BMI) 升高 (OR=1.083) 和怀孕期间使用胰岛素 (OR=2.704) 是产后葡萄糖不耐受症的重要危险因素.
- 在怀孕期间增加的BMI和胰岛素使用显示出统计学上显著的关联.
结论:
- 体重指数较高的女性或在怀孕期间需要胰岛素的女性需要密切监测产后葡萄糖不耐症.
- 这些发现可以为预防风险女性发展为2型糖尿病的策略提供信息.
更多相关视频
08:13Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test OGTT and Insulin Tolerance Test ITT
Published on: January 7, 2018
69.4K
06:11Author Spotlight: Exploring the Long-Term Health Impacts of Intracytoplasmic Sperm Injection on Offspring
Published on: May 17, 2024
772
相关概念视频
Pathophysiology of Diabetes
1.2K
Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
1.2K
Diabetes Mellitus: Type 2 and Gestational
3.0K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
3.0K
Oral Hypoglycemic Agents: Biguanides and Glitazones
310
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
310
Glucose Transporters
24.3K
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
24.3K
Hypoglycemia and Glucagon
351
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
351
Dipeptidyl Peptidase 4 Inhibitors
271
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
271
